Personal information

Countries

Russia

Activities

Collapse all

Employment (2)

Russian Cancer Research Center NN Blokhin: Moscow, RU

2022-03-11 to present | Medical Oncologist (Chemotherapy №4)
Employment
Source: Self-asserted source
Tatiana Tikhomirova

Russian Cancer Research Center NN Blokhin: Moscow, RU

2018-09-01 to 2020-09-01 | Resident (Chemotherapy №4)
Employment
Source: Self-asserted source
Tatiana Tikhomirova

Education and qualifications (3)

Russian Cancer Research Center NN Blokhin: Moscow, RU

2020-10-01 to 2023-10-01 | PhD
Education
Source: Self-asserted source
Tatiana Tikhomirova

Russian Cancer Research Center NN Blokhin: Moscow, RU

2018-09-01 to 2020-09-01 | Medical Oncologist (Chemotherapy №4)
Education
Source: Self-asserted source
Tatiana Tikhomirova

Peoples' Friendship University of Russia: Moscow, RU

2012-09-01 to 2018-06 | Doctor of Medicine degree, 2018
Education
Source: Self-asserted source
Tatiana Tikhomirova

Professional activities (1)

European Society for Medical Oncology: Lugano, CH

Membership
Source: Self-asserted source
Tatiana Tikhomirova

Works (8)

Impact of PARP inhibitor maintenance therapy after initial treatment on the efficacy of subsequent therapy in ovarian cancer: a propensity score matching analysis

Malignant tumours
2025-01-23 | Journal article
DOI: 10.18027/2224-5057-2024-020
Contributors: А. А. Rumyantsev; Т. Е. Tihomirova; А. S. Tsareva; S. L. Gutorov; А. N. Lud; А. P. Chernova; S. A. Tjulandin
Source: check_circle
Crossref
grade
Preferred source (of 3)‎

BRCA-associated ovarian cancer in the russian patient population. Analysis of the non-interventional study Ovatar

Malignant tumours
2024-01-16 | Journal article
DOI: 10.18027/2224-5057-2023-13-4-46-59
Part of ISSN: 2587-6813
Part of ISSN: 2224-5057
Contributors: T. T. Tikhomirova; A. S. Tyulyandina; A. A. Rumyantsev; E. R. Israelyan; T. V. Kekeeva; O. V. Vedrova; M. L. Filipenko; L. N. Lyubchenko; I. A. Demidova; E. N. Imyanitov et al.
Source: Self-asserted source
Tatiana Tikhomirova

Adenocarcinoma of mammary gland type of the vulva: rare clinical case and review of current literature

Gynecologic Oncology
2023 | Journal article
Contributors: Tatiana Tikhomirova; Yu. Zuraeva; R. I. Knyazev; A. A. Rumyantsev; A. S. Shevchuk
Source: Self-asserted source
Tatiana Tikhomirova

HRD Testing of Ovarian Cancer in Routine Practice: What Are We Dealing With?

International Journal of Molecular Sciences
2023-06-22 | Journal article
DOI: 10.3390/ijms241310497
Part of ISSN: 1422-0067
Contributors: Tatiana Kekeeva; Yulia Andreeva; Alexander Tanas; Alexey Kalinkin; Svetlana Khokhlova; Tatiana Tikhomirova; Alexandra Tyulyandina; Anatoly Popov; Maria Kuzmenko; Mikhail Volkonsky et al.
Source: Self-asserted source
Tatiana Tikhomirova

<i>BRCA</i>-associated ovarian cancer: a review of the current literature

Pelvic Surgery and Oncology
2022-09-07 | Journal article
DOI: 10.17650/2686-9594-2022-12-3-56-62
Contributors: T. E. Tikhomirova; A. S. Tyulyandina; A. A. Rumyantsev; M. E. Abramov; A. Yu. Anokhin; A. N. Lud; S. A. Tjulandin
Source: check_circle
Crossref

Ripretinib (DCC-2618): a new tyrosine kinase inhibitor for the treatment of metastatic gastrointestinal stromal tumors

Russian Journal of Oncology
2020-07-09 | Journal article
DOI: 10.18821/1028-9984-2020-25-1-4-8
Contributors: D.. A Filonenko; T. E. Tikhomirova; A. A. Meshcheryakov
Source: check_circle
Crossref

Successful treatment of a chemo-resistant gestational trophoblastic neoplasia using GEMOX. Clinical case

Russian Journal of Oncology
2020-07-09 | Journal article
DOI: 10.18821/1028-9984-2020-25-1-42-46
Contributors: A. A. Meshcheryakov; T. E. Tikhomirova; L. A. Meshcheryakova
Source: check_circle
Crossref

Optimal duration of adjuvant trastuzumab therapy in patients with HER2-possitive early breast cancer: whether the problem is resolved?

Modern Oncology
2018 | Journal article
DOI: 10.26442/1815-1434_2018.2.24-28
Part of ISSN: 1815-1434
Source: Self-asserted source
Tatiana Tikhomirova
How many people are using ORCID?